CAS 1229236-86-5|LY2784544|N-{3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-yl}-3-methyl-1H-pyrazol-5-amine|N-{3-[(4-chloro-2-fluorophenyl)methyl]-2-...

General Information

Structure

Molecular Formula

C₂₃H₂₅ClFN₇O

Molecular Mass

469.9423032

Exact Mass

469.17931436

Charge

InChI

InChI=1S/C23H25ClFN7O/c1-14-9-21(29-28-14)27-22-11-17(13-31-5-7-33-8-6-31)23-26-15(2)20(32(23)30-22)10-16-3-4-18(24)12-19(16)25/h3-4,9,11-12H,5-8,10,13H2,1-2H3,(H2,27,28,29,30)

InChIKey

SQSZANZGUXWJEA-UHFFFAOYSA-N

Canonic Smiles

Clc1ccc(c(c1)F)Cc1c(C)nc2n1nc(Nc1[nH]nc(c1)C)cc2CN1CCOCC1

Isomeric Smiles

c1c(nn2c(c1CN1CCOCC1)nc(c2Cc1ccc(cc1F)Cl)C)Nc1[nH]nc(c1)C

Calculated Properties

JChem

Acid pKa

14.144992

H Acceptors

H Donor

LogD (pH = 5.5)

2.6034193

LogD (pH = 7.4)

3.6270852

Log P

3.669102

Molar Refractivity

137.1041

Polarizability

47.083466

Polar Surface Area

83.37

Rotatable Bonds

Lipinski's Rule of Five

true

Data Source

Commercial Catalog

Academic Data

Data Source

Names and Identifiers

IUPAC name

N-{3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-yl}-3-methyl-1H-pyrazol-5-amine

Synonyms

LY2784544

IUPAC Traditional name

N-{3-[(4-chloro-2-fluorophenyl)methyl]-2-methyl-8-(morpholin-4-ylmethyl)imidazo[1,2-b]pyridazin-6-yl}-5-methyl-2H-pyrazol-3-amine

Names and Identifiers

Registration numbers

CAS Number

1229236-86-5

PubChem SID

162037797

PubChem CID

46213929

Registration numbers

Properties

Pharmacology Properties

Target

JAK

Safety Information

Storage Condition

-20°C

Product Information

Salt Data

Free Base

Properties

Related Proteins

No Data Available

Click here to submit data

Molecular Spectra

No Data Available

Click here to submit data

Molecule Details

Selleck Chemicals

S2179

Research Area

Description

Myeloproliferative disorders

Biological Activity

Description

LY2784544 is selective to V617F mutant JAK2 with IC50 of 55 nM in Ba/F3 cells.

Targets

JAK2 V617F mutant

IC₅₀

55 nM ^[1]

In Vitro

LY2784544 also inhibits IL-3-activated wild type JAK2 with IC50 of 2.26 μM. Similarly in the proliferation assay, LY2784544 shows antiproliferation activity in JAK2 V617F-driven cells with IC50 of 68 nM, compared to 1.36 μM in wild type JAK2-driven cells and 0.94 μM in JAK3-driven cells. ^[1]

In Vivo

LY2784544 significantly inhibits STAT5 phosphorylation in Ba/F3-JAK2 V617F-GFP xenografts with a Threshold Effective Dose 50 (TED50) of 12.7 mg/kg. LY2784544 also reduces Ba/F3-JAK2 V617F-GFP tumor burden in the JAK2 V617F-induced MPN model with a TED50 of 13.7 mg/kg after oral treatment. LY2784544 has no effect on CD71/Ter119 positive erythroid progenitors in spleens of SCID mice after oral treatment. ^[1]

Clinical Trials

Currently in Phase I clinical trial in patients with JAK2 V617F-positive myeloproliferative disorders.

Features